Nuvalent ALKOVE-1 Data Boosts NSCLC Targeted Therapy
Cambridge, Massachusetts, USA, April 21, 2026 In a major advancement for targeted cancer therapy, Nuvalent, Inc. has announced the...
lung cancer
Advertisement
Revolution Medicines Reports Breakthrough Zoldonrasib Data
REDWOOD CITY, Calif., April 19, 2026 A major breakthrough in targeted oncology therapy has emerged as Revolution Medicines unveiled...
MAIA Activates U.S. Site for Phase 2 Lung Cancer Trial
CHICAGO, April 16, 2026 MAIA Biotechnology, Inc. has announced the activation of its first U.S. clinical site for the...
Boehringer Ingelheim Zongertinib Shows Strong NSCLC Results
INGELHEIM, Germany, April 16, 2026 Boehringer Ingelheim has announced the publication of Phase 1b Beamion LUNG-1 trial results for...
Geminii Shows Promising NSCLC Data for Bioelectronic Therapy
CHICAGO, April 16, 2026 Geminii, Inc. has announced the presentation of new preclinical data on its bioelectronic therapy platform...
Advertisements
Adagene Reports Strong Muzastotug KEYTRUDA CRC Data
San Diego, USA & Suzhou, China, April 2, 2026 Strong Clinical Efficacy in MSS Colorectal Cancer In a major...
IDEAYA Biosciences Doses First Patient in IDE574 Trial
South San Francisco, California, USA, April 6, 2026 First-in-Class Epigenetic Therapy Enters Clinical Development In a major step forward...
ImmunityBio Expands ANKTIVA Access in Saudi Arabia
SAN DIEGO & RIYADH — February 20, 2026 — Immunotherapy innovator ImmunityBio has announced a strategic partnership with regional...
Whitehawk Therapeutics Identifies PTK7 as a Broadly Expressed ADC Target Across Solid Tumors
MORRISTOWN, N.J. | October 24, 2025 — Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology-focused biopharmaceutical company pioneering next-generation antibody-drug...
FDA Grants Breakthrough Therapy Status to Olomorasib for Lung Cancer
INDIANAPOLIS, Sept. 4, 2025 – The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib,...
Advertisement
